Wells Fargo & Company Lowers Enovis (NYSE:ENOV) Price Target to $33.00

Enovis (NYSE:ENOV) had its target price cut by investment analysts at Wells Fargo & Company from $39.00 to $33.00 in a report issued on Wednesday, Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 59.64% from the stock’s previous close.

Other analysts have also recently issued reports about the company. Citizens Jmp lowered their target price on Enovis from $55.00 to $47.00 and set a “market outperform” rating on the stock in a research report on Wednesday. BTIG Research decreased their price target on Enovis from $40.00 to $36.00 and set a “buy” rating for the company in a research note on Tuesday. BMO Capital Markets set a $27.00 price target on Enovis in a report on Tuesday. Weiss Ratings raised Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, July 21st. Finally, UBS Group reaffirmed a “buy” rating and issued a $51.00 price objective (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Enovis presently has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Enovis Stock Performance

NYSE ENOV traded up $0.14 on Wednesday, hitting $20.67. The stock had a trading volume of 330,259 shares, compared to its average volume of 1,091,172. The company’s 50-day moving average is $25.65 and its two-hundred day moving average is $24.27. Enovis has a one year low of $19.14 and a one year high of $34.28. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -1.07 and a beta of 1.32. The company has a quick ratio of 1.00, a current ratio of 1.98 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.90 earnings per share for the quarter, beating analysts’ consensus estimates of $0.85 by $0.05. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The business’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.79 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts expect that Enovis will post 3.15 earnings per share for the current year.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were purchased at an average cost of $21.62 per share, for a total transaction of $25,944.00. Following the completion of the transaction, the insider owned 51,840 shares in the company, valued at $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought 3,200 shares of company stock valued at $69,864 in the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Trading of Enovis

A number of large investors have recently added to or reduced their stakes in ENOV. Arax Advisory Partners acquired a new stake in shares of Enovis during the 4th quarter valued at $29,000. Allworth Financial LP purchased a new stake in shares of Enovis during the second quarter valued at $36,000. EverSource Wealth Advisors LLC boosted its position in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares during the period. Public Employees Retirement System of Ohio purchased a new position in Enovis in the 2nd quarter worth about $48,000. Finally, Danske Bank A S purchased a new position in Enovis in the 3rd quarter worth about $64,000. 98.45% of the stock is currently owned by institutional investors.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Citizens JMP maintained a “Market Outperform” rating on Enovis (ENOV) while lowering its price target from $55 to $47. The revised target still implies substantial upside from the recent share price, suggesting the analyst believes the selloff may be excessive. Benzinga analyst price target report
• Positive Sentiment: Enovis entered into a binding offer to acquire eCential Robotics, a developer of surgical robotics and enabling technologies, for approximately €155 million, or about $180 million. The deal would add robotic automation to Enovis’ ASTRA platform and could broaden its medical-device portfolio, improve surgical workflows and support future growth. Enovis announces eCential Robotics acquisition
• Neutral Sentiment: Management discussed the transaction and its strategic rationale in an M&A call, giving investors more detail on the planned expansion into surgical robotics. The near-term financial impact and execution timeline remain key areas for investors to evaluate. Enovis M&A call transcript
• Neutral Sentiment: Enovis is scheduled to participate in the Wells Fargo Healthcare Conference on September 8, potentially providing additional commentary on the acquisition, growth strategy and financial outlook. Enovis Wells Fargo Healthcare Conference announcement
• Negative Sentiment: The acquisition announcement triggered a steep decline in ENOV shares. Investors appear concerned about the $180 million purchase price, the risks of integrating eCential Robotics and the uncertainty surrounding commercialization of its surgical robot. Enovis shares fall after eCential Robotics offer

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.